Making it Possible

Envision a world where progressive myopia is a thing of the past.

With our transformative microdosing technology, we are developing a treatment for progressive myopia, a condition which is associated with several back of the eye diseases and may result in visual disability.

Play Video

See a child using the Optejet dispenser as part of his nighttime routine

Making it Possible

Envision a world where progressive myopia is a thing of the past.

With our transformative microdosing technology, we are developing a treatment for progressive myopia, a condition which is associated with several back of the eye diseases and may result in visual disability.

Latest News

01/06/21

Eyenovia to Participate in Presbyopia Panel Discussion at the LifeSci Partners 10th Annual Corporate Access Event

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) — Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer, will participate in a panel discussion on presbyopia at the upcoming LifeSci Partners 10th Annual Corporate Access Event.

Read More

12/29/20

EYENOVIA SUBMITS NEW DRUG APPLICATION TO FDA FOR PHARMACOLOGIC MYDRIASIS WITH MYDCOMBI TARGETING 80 MILLION PATIENT ENCOUNTERS IN THE U.S. ANNUALLY

NEW YORK–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company with Phase 3 programs in presbyopia, myopia and mydriasis, today announced that it has submitted a New Drug Application (NDA) to the U. S. Food and Drug Administration (FDA) for MydCombi™…

Read More

12/20/20

Eyenovia announces first patients enrolled in phase 3 study of microline for presbyopia


NEW YORK–(BUSINESS WIRE)–Eyenovia, Inc. (NASDAQ: EYEN), a clinical-stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the first set of patients has been enrolled in the Company’s Phase 3 VISION-1 study of MicroLine, its proprietary pilocarpine formulation delivered via its Optejet® dispenser, for the improvement in near vision in patients with presbyopia.

Read More

11/10/20

EYENOVIA TO REPORT THIRD QUARTER 2020 RESULTS

Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020, after market close.

Read More

 
 

 

A Transformative Biopharmaceutical Company

Eyenovia is a clinical stage, ophthalmic biopharmaceutical company that is transforming therapies primarily for the treatment of progressive myopia, presbyopia, and improving diagnostic eye exams. We believe our breakthrough technology enables these first-in-class microdosed therapies that are designed to reduce ocular and systemic toxicity and improve the risk-benefit profile of both new and existing drugs.

See How We Make it Possible

Vision-Logo-120619v2

Vision

VISION, our phase III NDA enabling study for the temporary improvement in sight for adults with presbyopia
is scheduled to enroll and complete in 2020.

More information coming soon!

These results showed the efficacy and safety of the fixed combination microdose formulation
and the potential for offices to improve their patient flow. 

Close Menu